Compare EEFT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | NRIX |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 1996 | 2020 |
| Metric | EEFT | NRIX |
|---|---|---|
| Price | $72.99 | $23.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $95.00 | $30.50 |
| AVG Volume (30 Days) | 671.5K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.05 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $4,244,200,000.00 | $76,987,000.00 |
| Revenue This Year | $8.17 | N/A |
| Revenue Next Year | $5.97 | $48.05 |
| P/E Ratio | $88.52 | ★ N/A |
| Revenue Growth | 6.38 | ★ 99.31 |
| 52 Week Low | $62.50 | $8.20 |
| 52 Week High | $98.52 | $25.09 |
| Indicator | EEFT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | N/A |
| Support Level | $72.35 | N/A |
| Resistance Level | $75.49 | N/A |
| Average True Range (ATR) | 2.67 | 0.00 |
| MACD | -1.16 | 0.00 |
| Stochastic Oscillator | 14.85 | 0.00 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing, and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.